Logo image of RARE

ULTRAGENYX PHARMACEUTICAL IN (RARE) Stock Fundamental Analysis

NASDAQ:RARE - Nasdaq - US90400D1081 - Common Stock - Currency: USD

39.91  +0.45 (+1.14%)

After market: 39.91 0 (0%)

Fundamental Rating

4

Overall RARE gets a fundamental rating of 4 out of 10. We evaluated RARE against 555 industry peers in the Biotechnology industry. RARE scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. RARE shows excellent growth, but is valued quite expensive already.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

RARE had negative earnings in the past year.
In the past year RARE has reported a negative cash flow from operations.
In the past 5 years RARE always reported negative net income.
In the past 5 years RARE always reported negative operating cash flow.
RARE Yearly Net Income VS EBIT VS OCF VS FCFRARE Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -200M -400M -600M

1.2 Ratios

RARE has a Return On Assets (-41.89%) which is comparable to the rest of the industry.
The Return On Equity of RARE (-381.00%) is worse than 75.14% of its industry peers.
Industry RankSector Rank
ROA -41.89%
ROE -381%
ROIC N/A
ROA(3y)-41.44%
ROA(5y)-32.95%
ROE(3y)-214.63%
ROE(5y)-141.85%
ROIC(3y)N/A
ROIC(5y)N/A
RARE Yearly ROA, ROE, ROICRARE Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -50 -100 -150 -200

1.3 Margins

With an excellent Gross Margin value of 85.13%, RARE belongs to the best of the industry, outperforming 88.29% of the companies in the same industry.
RARE's Gross Margin has been stable in the last couple of years.
The Profit Margin and Operating Margin are not available for RARE so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 85.13%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-3.3%
GM growth 5Y-1.12%
RARE Yearly Profit, Operating, Gross MarginsRARE Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -50K -100K -150K -200K

More info and screens

6

2. Health

2.1 Basic Checks

RARE does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, RARE has more shares outstanding
RARE has more shares outstanding than it did 5 years ago.
There is no outstanding debt for RARE. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
RARE Yearly Shares OutstandingRARE Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M
RARE Yearly Total Debt VS Total AssetsRARE Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 500M 1B 1.5B

2.2 Solvency

Based on the Altman-Z score of -2.91, we must say that RARE is in the distress zone and has some risk of bankruptcy.
RARE's Altman-Z score of -2.91 is in line compared to the rest of the industry. RARE outperforms 48.47% of its industry peers.
RARE has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -2.91
ROIC/WACCN/A
WACC8.99%
RARE Yearly LT Debt VS Equity VS FCFRARE Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 500M -500M 1B

2.3 Liquidity

A Current Ratio of 2.40 indicates that RARE has no problem at all paying its short term obligations.
The Current ratio of RARE (2.40) is worse than 70.81% of its industry peers.
RARE has a Quick Ratio of 2.24. This indicates that RARE is financially healthy and has no problem in meeting its short term obligations.
The Quick ratio of RARE (2.24) is worse than 70.81% of its industry peers.
Industry RankSector Rank
Current Ratio 2.4
Quick Ratio 2.24
RARE Yearly Current Assets VS Current LiabilitesRARE Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M 1B

More info and screens

7

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 26.77% over the past year.
RARE shows a strong growth in Revenue. In the last year, the Revenue has grown by 33.45%.
The Revenue has been growing by 40.13% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)26.77%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%22.66%
Revenue 1Y (TTM)33.45%
Revenue growth 3Y16.82%
Revenue growth 5Y40.13%
Sales Q2Q%27.99%

3.2 Future

RARE is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 27.92% yearly.
The Revenue is expected to grow by 35.21% on average over the next years. This is a very strong growth
EPS Next Y20%
EPS Next 2Y19.77%
EPS Next 3Y22.79%
EPS Next 5Y27.92%
Revenue Next Year19.34%
Revenue Next 2Y24.04%
Revenue Next 3Y31.2%
Revenue Next 5Y35.21%

3.3 Evolution

The Revenue growth rate is stable: in the next years the growth will be about the same than in the last years.
RARE Yearly Revenue VS EstimatesRARE Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 1B 2B 3B 4B
RARE Yearly EPS VS EstimatesRARE Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 0 5 -5 10 -10 15

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for RARE. In the last year negative earnings were reported.
Also next year RARE is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
RARE Price Earnings VS Forward Price EarningsRARE Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80 100

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
RARE Per share dataRARE EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4 -4 6

4.3 Compensation for Growth

A more expensive valuation may be justified as RARE's earnings are expected to grow with 22.79% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y19.77%
EPS Next 3Y22.79%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for RARE!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ULTRAGENYX PHARMACEUTICAL IN

NASDAQ:RARE (7/3/2025, 8:03:08 PM)

After market: 39.91 0 (0%)

39.91

+0.45 (+1.14%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-06 2025-05-06/amc
Earnings (Next)07-30 2025-07-30/amc
Inst Owners97.63%
Inst Owner Change2.94%
Ins Owners3.57%
Ins Owner Change12.55%
Market Cap3.77B
Analysts85.19
Price Target92.22 (131.07%)
Short Float %6.74%
Short Ratio5.83
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-0.52%
Min EPS beat(2)-5.63%
Max EPS beat(2)4.6%
EPS beat(4)3
Avg EPS beat(4)4.09%
Min EPS beat(4)-5.63%
Max EPS beat(4)12.01%
EPS beat(8)4
Avg EPS beat(8)-0.27%
EPS beat(12)5
Avg EPS beat(12)-11.02%
EPS beat(16)6
Avg EPS beat(16)-12.08%
Revenue beat(2)1
Avg Revenue beat(2)-0.51%
Min Revenue beat(2)-5.05%
Max Revenue beat(2)4.02%
Revenue beat(4)3
Avg Revenue beat(4)4.18%
Min Revenue beat(4)-5.05%
Max Revenue beat(4)17.02%
Revenue beat(8)5
Avg Revenue beat(8)0.29%
Revenue beat(12)6
Avg Revenue beat(12)-1.23%
Revenue beat(16)6
Avg Revenue beat(16)-1.63%
PT rev (1m)-0.89%
PT rev (3m)-2.37%
EPS NQ rev (1m)-0.51%
EPS NQ rev (3m)2.87%
EPS NY rev (1m)5.27%
EPS NY rev (3m)2.71%
Revenue NQ rev (1m)-0.07%
Revenue NQ rev (3m)-0.58%
Revenue NY rev (1m)0.22%
Revenue NY rev (3m)-0.18%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 6.39
P/FCF N/A
P/OCF N/A
P/B 26.16
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-5.88
EYN/A
EPS(NY)-3.59
Fwd EYN/A
FCF(TTM)-4.37
FCFYN/A
OCF(TTM)-4.12
OCFYN/A
SpS6.25
BVpS1.53
TBVpS-0.81
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -41.89%
ROE -381%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 85.13%
FCFM N/A
ROA(3y)-41.44%
ROA(5y)-32.95%
ROE(3y)-214.63%
ROE(5y)-141.85%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-3.3%
GM growth 5Y-1.12%
F-Score4
Asset Turnover0.45
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 64.74%
Cap/Sales 3.91%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.4
Quick Ratio 2.24
Altman-Z -2.91
F-Score4
WACC8.99%
ROIC/WACCN/A
Cap/Depr(3y)346.02%
Cap/Depr(5y)389.65%
Cap/Sales(3y)18.19%
Cap/Sales(5y)18.31%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)26.77%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%22.66%
EPS Next Y20%
EPS Next 2Y19.77%
EPS Next 3Y22.79%
EPS Next 5Y27.92%
Revenue 1Y (TTM)33.45%
Revenue growth 3Y16.82%
Revenue growth 5Y40.13%
Sales Q2Q%27.99%
Revenue Next Year19.34%
Revenue Next 2Y24.04%
Revenue Next 3Y31.2%
Revenue Next 5Y35.21%
EBIT growth 1Y11.53%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year12.78%
EBIT Next 3Y29.61%
EBIT Next 5YN/A
FCF growth 1Y21.89%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y7.12%
OCF growth 3YN/A
OCF growth 5YN/A